Equity Analyst - Asia Consumer Sector, Investory

Devi Subhakesan

Equity Research experience of over 20 years include working at leading Asset Management and Brokerage/Investment Banking Firms.  

I focus primarily on the Asia consumer sector and analyse emerging trends and evolving consumption behaviours to publish investment insights on segments where women and/or youth drive purchasing decisions.

My approach combines in-depth industry and company research with rigorous valuation analysis to help investors make informed investment decisions.

Equity Analyst - Asia Consumer Sector

Reliance, Amazon Onboard Online Pharma Retail in India; Sector Now Set for Explosive Growth

ASIA CONSUMER: INSIGHTS AND INVESTMENT IDEAS

Investory

Investory is a Singapore-based boutique independent equity research firm founded in January 2017 with a primary focus on consumption themes across Asia-Pacific.

We aim to generate investible ideas based on consumption trends and outlook. We screen our ideas on several parameters - product potential, long-term growth and management commitment being the most critical.  We follow a fundamental analysis approach in our stock selection process and are not restricted by market cap.

We aspire to grow into a leading source of unbiased research, free of conflict of interest, for investors yearning for independent and disciplined analysis. 

We also undertake bespoke research mandates to support our Institutional clients’ investment needs.

Our team comprises of professionals with extensive experience in the Asian equity markets, in areas ranging from research, servicing institutional clients and investment management.

Event-Driven

In this insight, we analyze the details of Pharmeasy's acquisition of Thyrocare, rationale and boost to valuations, its impact on Thyrocare shares, and present a quick overview of India's pharma retail landscape.<a href="https://www.smartkarma.com/entities/pharmeasy" target="_blank" data-smartkarma-citation="entities:33473:1" rel="noopener">Pharmeasy (1416151D IN)</a>, India's leading e-pharmacy backed by established Private Equity players including Bessemer Ventures, Prosus (formerly Naspers), Temasek holdings, TPG, etc has boosted its valuation and expanded its business scope at one stroke with the acquisition of <a href="https://www.smartkarma.com/entities/thyrocare-technologies-ltd" target="_blank" data-smartkarma-citation="entities:22694:1" rel="noopener">Thyrocare Technologies (THYROCAR IN)</a>, a leading listed diagnostic chain in India. Pharmeasy is reportedly targeting to list its shares in India as soon as 2022. With COVID-led accelerated growth in demand for e-pharmacies and diagnostic/healthcare services, the sector has been in the limelight over the past year. Post this acquisition, Pharmeasy will be the only integrated health care tech play with a pan-India omnichannel presence spanning across the outpatient medical services spectrum. In our earlier report <a href="https://www.smartkarma.com/insights/reliance-amazon-onboard-online-pharma-retail-in-india-sector-now-set-for-explosive-growth" target="_blank" data-smartkarma-citation="insights:42377" rel="noopener">Reliance, Amazon Onboard Online Pharma Retail in India; Sector Now Set for Explosive Growth</a> we discussed in detail India's rapidly growing online pharma retail sector triggered by COVID-led restrictions. The sector has witnessed rapid consolidation and it is widely expected that two of its leading players could list their shares within a year.

In this insight, we analyze the details of Pharmeasy's acquisition of Thyrocare, rationale and boost to valuations, its impact on Thyrocare shares, and present a quick overview of India's pharma retail landscape.Pharmeasy (1416151D IN), India's leading e-pharmacy backed by established Private Equity players including Bessemer Ventures, Prosus (formerly Naspers), Temasek holdings, TPG, etc has boosted its valuation and expanded its business scope at one stroke with the acquisition of Thyrocare Technologies (THYROCAR IN), a leading listed diagnostic chain in India. Pharmeasy is reportedly targeting to list its shares in India as soon as 2022. With COVID-led accelerated growth in demand for e-pharmacies and diagnostic/healthcare services, the sector has been in the limelight over the past year. Post this acquisition, Pharmeasy will be the only integrated health care tech play with a pan-India omnichannel presence spanning across the outpatient medical services spectrum. In our earlier report Reliance, Amazon Onboard Online Pharma Retail in India; Sector Now Set for Explosive Growth we discussed in detail India's rapidly growing online pharma retail sector triggered by COVID-led restrictions. The sector has witnessed rapid consolidation and it is widely expected that two of its leading players could list their shares within a year.

Pharmeasy Acquires Thyrocare: Pre-IPO Move Boosts Valuation & Expands Operations